ELITE PHARMACEUTICAL
ELI
ELI was delisted on the 20th of May, 2009.
3 hedge funds and large institutions have $60.1K invested in ELITE PHARMACEUTICAL in 2016 Q4 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.
11% less capital invested
Capital invested by funds: $67.6K → $60.1K (-$7.45K)
40% less funds holding
Funds holding: 5 → 3 (-2)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCA
Personal Capital Advisors
Redwood City,
California
|
-$4K |
| 2 |
VWM
Valley Wealth Managers
Paramus,
New Jersey
|
-$1K |
ELI Hedge Fund Activity: Q4 2016 in Review
3 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in ELITE PHARMACEUTICAL (ELI) for Q4 2016, worth a combined $60.1K — down 11% from $67.6K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of ELI and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Personal Capital Advisors, exiting entirely with an estimated $4K sold.
- 3 institutional investors held ELITE PHARMACEUTICAL (ELI) as of Q4 2016, down from 5 in Q3 2016.
- Funds reported $60.1K of ELITE PHARMACEUTICAL stock for Q4 2016, down 11% quarter-over-quarter.
- 0 funds opened new ELITE PHARMACEUTICAL positions in Q4 2016 and 2 closed out, a net change of -2 holders.
- The largest ELITE PHARMACEUTICAL seller in Q4 2016 was Personal Capital Advisors, an estimated $4K sold.
Based on aggregated 13F filings for Q4 2016.